Argenx
ARGX
#468
Rank
A$76.76 B
Marketcap
A$1,227
Share price
0.12%
Change (1 day)
25.11%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Cash on Hand

Cash on Hand as of December 2025 : A$6.29 Billion

According to Argenx 's latest financial reports the company has A$6.29 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Argenx - Cash on Hand chart (from 2019 to 2020)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31A$6.62 B22.03%
2024-12-31A$5.43 B16.39%
2023-12-31A$4.66 B44.86%
2022-12-31A$3.22 B-0.04%
2021-12-31A$3.22 B24.14%
2020-12-31A$2.59 B21.14%
2019-12-31A$2.14 B104.38%
2018-12-31A$1.04 B58.1%
2017-12-31A$0.66 B346.87%
2016-12-31A$0.14 B113.73%
2015-12-31A$69.45 M-31.33%
2014-12-31A$0.10 B103.75%
2013-12-31A$49.64 M78.94%
2012-12-31A$27.74 M-28.22%
2011-12-31A$38.64 M181.06%
2010-12-31A$13.75 M